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Various  treatment  options  are  available  for  hepatocellular 
carcinoma  (HCC);  however,  the  overwhelming  majority  of 
them fail to extend patient survival, especially in cases of 
advanced disease. Although a number of different genetic 
lesions have been linked to HCC, the expression of onco-
genic microRNAs (miRNAs), such as miR-221 and miR-222, 
are consistently found elevated in HCC tumor specimens,1,2 
suggesting  that  silencing  of  these  miRNAs  might  slow  or 
stop tumor growth. In a recent study, Park et al. show that 
systemic administration of a chemically modified oligonucle-
otide that binds to and sequesters miR-221 is efficacious in 
HCC.3 Their approach identified a preferred chemical modifi-
cation on the oligonucleotide that allowed its accumulation in 
hepatocytes, which led to therapeutic silencing of miR-221, 
reduced cellular proliferation, and most importantly increased 
survival of an orthotopic mouse model of HCC. Although this 
approach has yet to be tried in human patients, it appears 
likely  that  treatments  involving  miRNA  overexpression  or 
silencing, such as these, will translate efficiently.
HCC  is  the  fifth  most  prevalent  cancer  worldwide  and 
the  third  most  common  cause  of  cancer-related  deaths.4 
Molecular markers of the disease include genetic instabil-
ity, reexpression of telomerase reverse transcriptase, loss 
of cell-cycle checkpoint control, and inhibition of apoptotic 
signaling pathways, such as those mediated by p53. In addi-
tion, loss of heterozygosity of the insulin-like growth factor 
2  receptor  is  common.  Perhaps  somewhat  unexpectedly, 
post-translational activation of oncogenic proteins is hetero-
geneous in HCC, and therefore not very useful as a diagnos-
tic or a general treatment target. In contrast, miR-221 and 
miR-222,  which  target  cyclin-dependent  kinase  inhibitors, 
such as p27Kip1 and p57Kip2, drive sustained cell-cycle pro-
gression in HCC.5,6 They also suppress the tumor suppres-
sor PTEN and other inhibitors of the AKT signaling pathway, 
thereby contributing to enhanced HCC cell migration.7 
miRNAs  are  a  class  of  small,  untranslated,  RNA  poly-
merase-II transcribed genes that post-transcriptionally regu-
late the translation of messenger RNAs (mRNAs).8 The ability 
of a miRNA to regulate a gene stems from a 6-  nucleotide 
seed region in the miRNA that typically interacts with the 
3′ untranslated region of a mRNA, so as to prevent transla-
tion or induce degradation of the mRNA. Due to their small 
size, which contributes to their pleiotropic role in targeting a 
large number of critical protein-coding genes, misregulation 
of a single miRNA can give rise to multiple adverse cellu-
lar effects. Aberrant miRNA levels have been implicated in 
promoting and maintaining various disease states including 
cancer. In some cases, overexpression of single miRNA is 
sufficient to drive tumorigenesis, although its silencing leads 
to tumor regression9. Based on these findings, and on recent 
human tumor miRNA profiling studies that have confirmed 
altered levels of some key miRNAs, it is becoming increas-
ingly attractive to target these master gene-regulators in vivo 
with cancer therapeutics.
One mechanism to silence oncogenic miRNAs (oncomiRs), 
such as miR-221, takes advantage of their affinity for comple-
mentary sequences. Introducing a small molecule that has a 
higher affinity for the miRNA than that target mRNA or one 
that is in greater abundance than the target gene, can lead 
to miRNA sequestration (Figure 1). Although simple in prac-
tice, a great deal of research design and development has 
gone into creating these chemically modified miRNA com-
plementary  molecules,  termed  antagomirs10.  Of  the  many 
challenges in antagomir design, off-target induced toxicity, 
tissue distribution, and pharmacokinetics are some of the 
most important. Each of these points was addressed by Park 
and colleagues,3 who synthesized a total of ten antagomirs 
with various chemical modifications and tested their efficacy 
at inhibiting cellular proliferation in culture and ultimately their 
capacity to localize to the liver and decrease HCC in vivo. 
One of the most promising antagomir chemistries identified in 
the cell culture work was 2′-O-methyl, phosphorothioate. The 
phosphorothioate substitutes sulfur for one of the nonbridg-
ing oxygens in the nucleotide. This modification decreases 
the  likelihood  of  endo-  and  exonuclease  degradation  and 
also aids the oligonucleotide in crossing the lipid bilayer. A 
2′-O-methyl addition to each of the individual nucleotides is 
also a nuclease protective modification. Although the chemis-
try of the aforementioned antagomir had the strongest effect 
in culture, a cholesterol-tagged version showed better phar-
macokinetics in vivo, giving rise to a 50-fold enrichment in 
maximum liver concentration over the untagged oligonucle-
otide. The cholesterol-tagged anti-miR-221 reduced miR-221 
levels by 80–90% leading to elevations in miR-221 targets. 
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Following systemic delivery of the cholesterol-tagged anti-
miR-221 to orthotopic tumors, the G1 cell-cycle checkpoint 
inhibitors  p27Kip1  and  p57Kip2  were  elevated  approximately 
threefold. Increased p27Kip1 and p57Kip2 most likely contrib-
uted to loss of the cellular proliferation marker, Ki-67, and 
to reductions in tumor-volume doubling times. PTEN levels 
were  also  increased  in  cholesterol-tagged  anti-miR-221 
treated tumors. PTEN is a negative regulator of AKT signal-
ing and therefore its elevation is also most likely central to 
the decreased growth of the treated tumors. Finally, the lack 
of hepatocyte toxicity in these mice was also confirmed fol-
lowing treatment.
These results are quite promising; although the tumors 
still progressed, these mice were only treated for 2 weeks 
with little to no increase in the tumor volume during the 
treatment period. It is encouraging to envisage that altered 
dosing  schedules  might  improve  the  overall  outcome  in 
these animals. Because toxicity was not an issue with the 
current dose and treatment schedule, it is definitely within 
reason to propose additional dosing, increased dosing, or 
even more attractively, combinatorial approaches to therapy. 
For example, sorafenib is one of the only approved targeted 
therapies for HCC that is associated with increased overall 
survival, although the increase is only about 2–3 months11. 
Therefore,  combining  cholesterol-tagged  anti-miR-221 
with  current  chemotherapies  such  as  sorafenib  warrants 
exploration.
Certainly since the biology of miRNAs has unfolded, the 
therapeutic potential of these molecules has exploded8. The 
field is in on an upward trajectory to identify and confirm the 
best candidate miRNAs to silence, or in the case of tumor-
suppressive miRNAs, to reintroduce. In the case of HCC, 
miR-221  represents  a  valid  target  and  cholesterol-tagged 
antagomirs undoubtedly accumulate in the liver representing 
a major step towards targeted delivery. The challenge of the 
field is to continue to design and test the targeting ability of 
different chemical moieties on antagomirs and miRNAs such 
that they can be delivered adequately to the tissue/tumor of 
interest. As better delivery chemistries are developed and 
the biology of miRNAs continues to be unraveled, the poten-
tial for transitioning these antagomirs into a clinical setting for 
many cancers becomes a very achievable possibility.
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Figure 1  therapeutic use of antagomir-mir-221. When overexpressed in cancers such as HCC, miR-221 targets and suppresses the expression of 
tumor-suppressive target proteins, such as p27Kip1, p57Kip2, and PTEN. Decreased levels of these cell-cycle regulators promote continued cell division, a hallmark of 
cancer cells. Introducing an oligonucleotide with complementarity to miR-221 sequesters the latter and leads to derepression of the target genes. This restoration of 
p27Kip1, p57Kip2, and PTEN protein resumes normal cell-cycle control, and contributes to reduced cellular proliferation and perhaps tumor regression. HCC, hepatocel-
lular carcinoma. 
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